3 stocks that could skyrocket by 2027 thanks to the development of weight loss drugs

In recent years, stocks of companies focused on the treatment of obesity and diabetes have been gaining in popularity. Given the growing health problems associated with obesity, which the COVID-19 pandemic has further accentuated, this market seems very promising. The increasing number of obese people in the world and the increased awareness about the risks associated with excessive body weight are leading to a greater demand for effective solutions.

As health systems across the globe strive to better control these chronic conditions, the importance of pharmaceutical innovation in this area continues to grow. Technological advances and improved clinical practices are further supporting the development of new, more effective drugs. The following three companies could dominate the market and offer significant opportunities for investors in the coming years.

Eli Lilly $LLY

Eli Lilly, one of the world's leading pharmaceutical companies, specializes in developing drugs for a wide range of…

Read the full article for free?
Go ahead 👇

Do you have an account? Then log in . Or create a new one .

No comments yet
Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Menu StockBot
Tracker
Upgrade